Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. Th…


Argenx raised over $300 million in their US public offering

18 September 2018 - Read the press release here. Argenx is a Belgian clinical-stage biotechnology company, developing differentiated antibody-…

POPULAR TAGS

Good News for Galapagos

Written by ALB on in the category news with the tags , .


It has been a huge month for Galapagos, with press releases issued in rapid succession. The news is all positive; the company has, in a very short amount of time, launched their initial public offering (IPO) on the American stock./. market, raised $300 Mil within the first few hours of going public as well as seen several positive developments in clinical trials. Not to mention, the collaboration agreement regarding drug candidate MOR106, with Novartis and partner MorphoSys, coming into effect.

It’s safe to say, this Belgian behemoth is on a roll and things don’t look to be slowing down anytime soon. Experts predicted 2018 to be a good year for Belgian Biotech and life sciences companies; business is certainly living up to expectations so far. At BioVox, we are excited to see what the remaining months of the year will bring!

Galapagos news

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT
06 September 2018 - Read the press release here.

Gilead Sciences and Galapagos announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis.

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS
11 September 2018 - Read the press release here.

Gilead Sciences and Galapagos announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response/intolerance to biologic agents, achieved its primary endpoint.

• Filgotinib 100 mg and 200 mg Doses Achieved Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response to Biologic Agents.
• Both Filgotinib Doses also Achieved All Key Secondary Efficacy Endpoints, including Low Disease Activity and Clinical Remission.
• Tolerability of Filgotinib was Consistent with Previously Reported Studies.

MORPHOSYS AND GALAPAGOS ANNOUNCE US ANTITRUST CLEARANCE FOR GLOBAL LICENSE AGREEMENT FOR MOR106 WITH PHARMA PARTNER
12 September 2018 - Read the press release here.

Galapagos and MorphoSys announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106.

GALAPAGOS ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING
12 September 2018 - Read the press release here.

Galapagos announced that it intended to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares in a U.S. public offering.

GALAPAGOS RAISES $300 MILLION GROSS PROCEEDS IN A US PUBLIC OFFERING
13 September 2018 - Read the press release here.

Galapagos announced the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares at $116.50 per ADS, before underwriting discounts.

GALAPAGOS AND MORPHOSYS ANNOUNCE START OF A PHASE I SUBCUTANEOUS BRIDGING STUDY WITH MOR106
13 September 2018 - Read the press release here.

Galapagos and MorphoSys announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.

GALAPAGOS ANNOUNCES CLOSING OF PUBLIC OFFERING OF AMERICAN DEPOSITORY SHARES FOR GROSS PROCEEDS OF €296.2 MILLION
17 September 2018 - Read the press release here.

Galapagos  announced the closing of its underwritten public offering of 2,961,373 American Depositary Shares at a price of $116.50, before underwriting discounts, for gross proceeds of €296.2 million.

GALAPAGOS ISSUES NEW SHARES AS RESULT OF PUBLIC OFFERING
17 September 2018 - Read the press release here.

Galapagos announces a share capital increase as a result of a public offering of American Depositary Shares.

Read more about: , .

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. Th…


Argenx raised over $300 million in their US public offering

18 September 2018 - Read the press release here. Argenx is a Belgian clinical-stage biotechnology company, developing differentiated antibody-…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin Itera Life Science Turnstone Janssen GSK UGent XpandInnovation V-Bio Ventures Flanders.bio KU Leuven

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.